This is an archive of past discussions. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page. |
Archive 1 | Archive 2 |
Actavis have launched a generic version of pregabalin in the UK [1], unfortunately I haven't found an independent source for this. This was the result of a court case over the patent [2]. January ( talk) 14:13, 26 March 2015 (UTC)
Just to add a link from activis in support of previous posters assertion http://www.actavis.co.uk/en-gb/news/news/actavis-launches-pregabalin-capsules-%28lecaent%29
Addiction & dependence citation - page 25
|
---|
|
@ Eharlacher91: This is the relevant cited material from the reference in the drugbox. There are no references to psychological dependence at all in this section. The material relevant to addiction indicates that there are no known pharmacodynamic relationships with addictive drug targets and there's no statistically significant euphoriant effect relative to placebo. If you want to state that this drug is addictive in this article, that's perfectly fine so long as you cite an appropriate medical source which agrees with the statement.
I'd caution you against reverting these 2 drugbox parameters again without addressing the sourcing issue that I've raised here, as the WP:3RR policy is relevant at the moment. Seppi333 ( Insert 2¢) 04:09, 14 September 2015 (UTC)
This med is used for neuropathic pain but is not a general analgesic in that it does not appear to be useful for acute pain. Doc James ( talk · contribs · email) 15:03, 4 October 2015 (UTC)
@ Skullballoons: I am concerned that the current lede gives an impression of a general dependence liability that is a little bit excessive based on the available sources.
Given that this drug was used by millions of people, 73 isn't a lot of case reports. I'd suggest moving this material out of the lede and using more specific language than "There are indications of dependence for pregabalin in the European Union, relevant reports from Germany and Sweden", which is quite vague and could be interpreted as implying risk anywhere along a wide spectrum. I think the language I used referring to case reports would be a pretty accurate and reasonably precise description of what is in the literature. 70.214.20.118 ( talk) 19:28, 27 September 2015 (UTC)
Not sure why this was removed "As of 2015 no generic version is available in the United States. [1] In the United States its costs about 3 to 6 USD per day. [1]" [3] Doc James ( talk · contribs · email) 09:16, 24 October 2015 (UTC)
The side effects of a medication should be given only slightly less weight than the effects with meds always being a balance of benefits versus harms. Thus not sure why the well referenced side effects were removed from the lead [4] Doc James ( talk · contribs · email) 20:30, 24 October 2015 (UTC)
This is poorly supported
" It's well known to be a faster-acting drug with a rapid onset of action, prolonged duration, greater bioavailability, higher potency and stronger receptor binding affinity. Pregabalin is fives times more potent than gabapentin with a proven potential for abuse and dependence. Which ultimately led to its control in the United States. [2] [3]"
References
AHFS2015
was invoked but never defined (see the
help page).Doc James ( talk · contribs · email) 13:05, 23 October 2015 (UTC)
For pain I would not describe its onset as rapid. Its onset is over weeks. Half life is 5 to 7 hours for gabapentin while it is 6.3 hours for pregabalin. Hardly a difference. [8] [9] Bioavailability is not clinically important. Doc James ( talk · contribs · email) 07:09, 24 October 2015 (UTC)
While pregabalin binds more strongly that does not mean it works any better. "Potent" has different meaning. Potent in lay terminology means stronger / better. Thus moved to the body.
Doc James ( talk · contribs · email) 01:48, 28 November 2015 (UTC)
I have moved the brand names to the infobox. There are lots. We do not generally put them all in the lead.
Also we should try to have the lead and first paragraph in easier to understand language. And we often format the lead to follow MEDMOS / the body of the article Doc James ( talk · contribs · email) 11:24, 9 December 2015 (UTC)
If anyone wants to work on this, Sources: http://www.bloomberg.com/news/articles/2015-09-10/pfizer-made-groundless-threats-to-pharmacies-in-patent-dispute http://www.pharmaceutical-journal.com/news-and-analysis/news/pfizers-lyrica-gp-reimbursement-plan-under-scrutiny-by-industry-self-regulator/20069308.article? — Preceding unsigned comment added by 86.3.219.245 ( talk) 16:33, 28 February 2016 (UTC)
My apologies for making so many edits in order to properly format some citations. Tribe of Tiger Let's Purrfect! 23:03, 28 June 2020 (UTC)
This is an archive of past discussions. Do not edit the contents of this page. If you wish to start a new discussion or revive an old one, please do so on the current talk page. |
Archive 1 | Archive 2 |
Actavis have launched a generic version of pregabalin in the UK [1], unfortunately I haven't found an independent source for this. This was the result of a court case over the patent [2]. January ( talk) 14:13, 26 March 2015 (UTC)
Just to add a link from activis in support of previous posters assertion http://www.actavis.co.uk/en-gb/news/news/actavis-launches-pregabalin-capsules-%28lecaent%29
Addiction & dependence citation - page 25
|
---|
|
@ Eharlacher91: This is the relevant cited material from the reference in the drugbox. There are no references to psychological dependence at all in this section. The material relevant to addiction indicates that there are no known pharmacodynamic relationships with addictive drug targets and there's no statistically significant euphoriant effect relative to placebo. If you want to state that this drug is addictive in this article, that's perfectly fine so long as you cite an appropriate medical source which agrees with the statement.
I'd caution you against reverting these 2 drugbox parameters again without addressing the sourcing issue that I've raised here, as the WP:3RR policy is relevant at the moment. Seppi333 ( Insert 2¢) 04:09, 14 September 2015 (UTC)
This med is used for neuropathic pain but is not a general analgesic in that it does not appear to be useful for acute pain. Doc James ( talk · contribs · email) 15:03, 4 October 2015 (UTC)
@ Skullballoons: I am concerned that the current lede gives an impression of a general dependence liability that is a little bit excessive based on the available sources.
Given that this drug was used by millions of people, 73 isn't a lot of case reports. I'd suggest moving this material out of the lede and using more specific language than "There are indications of dependence for pregabalin in the European Union, relevant reports from Germany and Sweden", which is quite vague and could be interpreted as implying risk anywhere along a wide spectrum. I think the language I used referring to case reports would be a pretty accurate and reasonably precise description of what is in the literature. 70.214.20.118 ( talk) 19:28, 27 September 2015 (UTC)
Not sure why this was removed "As of 2015 no generic version is available in the United States. [1] In the United States its costs about 3 to 6 USD per day. [1]" [3] Doc James ( talk · contribs · email) 09:16, 24 October 2015 (UTC)
The side effects of a medication should be given only slightly less weight than the effects with meds always being a balance of benefits versus harms. Thus not sure why the well referenced side effects were removed from the lead [4] Doc James ( talk · contribs · email) 20:30, 24 October 2015 (UTC)
This is poorly supported
" It's well known to be a faster-acting drug with a rapid onset of action, prolonged duration, greater bioavailability, higher potency and stronger receptor binding affinity. Pregabalin is fives times more potent than gabapentin with a proven potential for abuse and dependence. Which ultimately led to its control in the United States. [2] [3]"
References
AHFS2015
was invoked but never defined (see the
help page).Doc James ( talk · contribs · email) 13:05, 23 October 2015 (UTC)
For pain I would not describe its onset as rapid. Its onset is over weeks. Half life is 5 to 7 hours for gabapentin while it is 6.3 hours for pregabalin. Hardly a difference. [8] [9] Bioavailability is not clinically important. Doc James ( talk · contribs · email) 07:09, 24 October 2015 (UTC)
While pregabalin binds more strongly that does not mean it works any better. "Potent" has different meaning. Potent in lay terminology means stronger / better. Thus moved to the body.
Doc James ( talk · contribs · email) 01:48, 28 November 2015 (UTC)
I have moved the brand names to the infobox. There are lots. We do not generally put them all in the lead.
Also we should try to have the lead and first paragraph in easier to understand language. And we often format the lead to follow MEDMOS / the body of the article Doc James ( talk · contribs · email) 11:24, 9 December 2015 (UTC)
If anyone wants to work on this, Sources: http://www.bloomberg.com/news/articles/2015-09-10/pfizer-made-groundless-threats-to-pharmacies-in-patent-dispute http://www.pharmaceutical-journal.com/news-and-analysis/news/pfizers-lyrica-gp-reimbursement-plan-under-scrutiny-by-industry-self-regulator/20069308.article? — Preceding unsigned comment added by 86.3.219.245 ( talk) 16:33, 28 February 2016 (UTC)
My apologies for making so many edits in order to properly format some citations. Tribe of Tiger Let's Purrfect! 23:03, 28 June 2020 (UTC)